In accordance with the Merger Agreement, immediately prior to the Effective Time, Dr. Samir Khleif resigned from the Board of the Ayala Pharmaceuticals, Inc. Mr. Khleif had been a member of the Nominating and Corporate Governance Committee and Research and Development Committee. The resignation was not the result of any disagreements with the Registrant relating to the Registrant's operations, policies or practices. In accordance with the Merger Agreement, effective immediately after the Effective Time, the following individuals were appointed to the Board of the Ayala Pharmaceuticals, Inc. Yuval Cabilly, Ph.D. Dr. Cabilly, 43, previously served as a director of Biosight.

Dr. Cabilly is the Co-Founder and Managing Partner of Israel Biotech Fund. Dr. Cabilly received his PhD in molecular cell biology from Tel Aviv University, where his research focused on a neurodegenerative disease, and several of his articles have been published in well-known scientific journals. The company believe that Dr. Orbach's extensive experience identifying, funding and engaging in business development activities in the life-science industry qualifies him to serve on the Board.

Pini Orbach, Ph.D. Dr. Orbach, 59, previously served as a director of Biosight. Dr. Orbach is the Head of the Pharma Division of Arkin Holdings and a board member of several pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. Dr. Orbach has experience with United States based pharmaceutical companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals, as well as Israeli-based companies cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M.

Dr. Orbach holds a PhD from the University of Florida, and was a postdoctoral fellow at Harvard Medical School Massachusetts General Hospital. The company believe that Dr. Orbach's extensive experience in the life-science industry qualifies him to serve on the Board. Bridget Martell, M.D. Dr. Martell is a seasoned biopharmaceutical corporate executive with a demonstrated track record in financing, building, and leading highly successful companies.

She has served in numerous C-Suite, Venture, and Independent Board roles, most recently President and Chief Executive Officer of Artizan Biosciences, Inc., a part-time Healthcare Venture Partner with AlleyCorp, an early stage venture capital company, and as an independent board director of Achieve Life Sciences, Aligos Therapeutics, and POINT Biopharma (acquired by Lilly, September 2023). Under the auspice of her consulting practice, BAM Consultants LLC, Dr. Martell has held various leadership positions in early stage to late stage public and private companies, including Chief Medical Officer of three private and two publicly traded companies as well as at RRD International, a boutique Contract Research Organization (acquired by Uniphar in 2021). Dr. Martell began her Pharmaceutical career at Pfizer were she held leadership roles of increasing responsibility at from 2005 to 2011.

Dr. Martell earned her B.S. in microbiology from Cornell University, her M.A. in molecular immunology from Boston University and her M.D. from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Dr. Martell is board certified in both internal and addiction medicine.